

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: PEPYS

Patent No.: 7,045,499 B2

Application No.: 09/985,699

Issued: May 16, 2006

Filed: November 5, 2001

Title: THERAPEUTIC AGENT

**REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 C.F.R. § 1.323
(APPLICANT'S MISTAKE)**

Commissioner for Patents

Washington, D.C. 20231


Attn: Certificate of Correction Branch

Sir:

Pursuant to 37 C.F.R. § 1.323, Patentee respectfully requests that a Certificate of Correction be issued in the above-identified U.S. patent to correct the following errors.

Claims 1 and 2 should be corrected by deleting from the claims the expression:

“ wherein R is the group



In a response filed July 15, 2005 to a restriction requirement dated February 18, 2005 requiring that the claims specify the D-proline compound of claim 20, claims 1 and 2 were amended to be directed to a method wherein the D-proline is the compound of claim 20, but inadvertently included in the statement of the compound of claim 20 the above expression from claim 19, on which claim 20 depends. The above expression clearly does not relate to the compound of claim 20, which is:

“(R)-1-[6-(R)-2-Carboxypyrrolidin-1-yl]-6-oxo-hexanoyl] pyrrolidine-2-carboxylic acid or a pharmaceutically acceptable salt or mono- or diester thereof.”

and its inclusion in claims 1 and 2 with the compound of claim 20 is a typographical error.

The following typographical errors were noted in the abstract. Specifically, in line 4 of the abstract, "whierein" should be replacaed with --wherein--; in line 6 of the abstract, "non-protein access" should be replaced with --non-proteinaceous--.

The following typographical errors were noted in the specification. Specifically, in column 2, line 22, the citation "(1-5) U.S. Patent No. 6,126,918)" should read as (1-5; and U.S. Patent No. 6,126,918) by replacing the right parenthesis after "5" with a semicolon followed by the word "and". Also, in column 15, line 14, the group "R₃C" of the depicted compound should be replaced with F₃C, as shown on page 24 of the originally filed application.

Attached is a Form PTO-1050 showing the necessary corrections. Patentee respectfully requests that the form be entered and a copy returned to the undersigned. (Pursuant to the guidelines in the recent Official Gazette Notice at 1262 OG 96, the form is not being submitted in duplicate.) Please charge the \$100 fee for this request under 37 C.F.R. § 1.20(a), and any other fees that may be due in connection with this request to our Deposit Account, No. 03-3975.

Respectfully submitted,

PILLSBURY WINTHROP SHAW PITTMAN LLP

Date: August 29, 2006

By: 
Thomas A. Cawley, Jr., Ph.D.
Registration No. 40,944

1650 Tysons Boulevard
McLean, VA 22102
(703) 770-7900 Telephone
(703) 770-7901 Facsimile

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO. : 7,045,499

APPLICATION NO.: 09/985,699

ISSUE DATE : May 16, 2006


INVENTOR(S) : Mark Pepys

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:


In the Abstract: Line 4, change "whierein" to --wherein--;
 Line 6, change "non-protein access" to --non-proteinaceous--;

In the Specification: Column 2, line 22, change "(1-5) U.S. Patent No. 6,126,918)" to
 --(1-5; and U.S. Patent No. 6,126,918)--;
 Column 15, line 14, change "R₃C" to --F₃C--.

In the Claims: Claim 1, which appears at column 20, lines 2-12, delete the expression:
 "wherein R is the group



Claim 2, which appears at column 20, lines 29-38, delete the expression
 "wherein R is the group



MAILING ADDRESS OF SENDER (Please do not use customer number below):

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.